Beacon Investment Advisory Services Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Beacon Investment Advisory Services Inc. lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 92.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 757 shares of the biopharmaceutical company’s stock after selling 9,055 shares during the period. Beacon Investment Advisory Services Inc.’s holdings in Regeneron Pharmaceuticals were worth $472,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. BayBridge Capital Group LLC grew its position in shares of Regeneron Pharmaceuticals by 91.9% in the second quarter. BayBridge Capital Group LLC now owns 808 shares of the biopharmaceutical company’s stock valued at $504,000 after purchasing an additional 387 shares during the last quarter. Arizona State Retirement System raised its position in shares of Regeneron Pharmaceuticals by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 28,831 shares of the biopharmaceutical company’s stock worth $17,977,000 after purchasing an additional 533 shares during the last quarter. West Family Investments Inc. lifted its stake in Regeneron Pharmaceuticals by 71.2% in the 2nd quarter. West Family Investments Inc. now owns 1,017 shares of the biopharmaceutical company’s stock valued at $634,000 after buying an additional 423 shares in the last quarter. Carmignac Gestion lifted its stake in Regeneron Pharmaceuticals by 56.6% in the 2nd quarter. Carmignac Gestion now owns 182,507 shares of the biopharmaceutical company’s stock valued at $113,827,000 after buying an additional 65,936 shares in the last quarter. Finally, Nykredit A S purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $23,968,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of REGN opened at $807.65 on Thursday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $859.34. The company has a market capitalization of $83.16 billion, a PE ratio of 19.96, a price-to-earnings-growth ratio of 1.59 and a beta of 0.20. The stock has a fifty day moving average of $749.60 and a two-hundred day moving average of $720.06. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the firm earned $12.81 earnings per share. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent research reports. Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Royal Bank Of Canada upped their price objective on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research report on Friday, July 31st. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Citigroup lifted their price objective on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Fourteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $800.36.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,146 shares of company stock valued at $3,432,488 in the last quarter. Corporate insiders own 6.97% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron’s presentation at the Wells Fargo Healthcare Conference may provide investors with additional detail on its pipeline, commercial portfolio and strategy. However, the available report is a transcript and does not identify a new market-moving announcement. Wells Fargo conference transcript
• Neutral Sentiment: Recent fund commentary is mixed: Harbor Funds discussed the stock’s bullish potential, while American Century Investments reported selling its Regeneron position. These manager opinions may influence sentiment but do not change the company’s fundamentals. Harbor Funds commentary American Century fund sale
• Negative Sentiment: Several firms reiterated that investors who purchased REGN between August 1, 2025 and May 15, 2026 may seek lead-plaintiff status by September 14, 2026. The allegations focus on whether Regeneron adequately disclosed the protocol and risks of the Phase 3 fianlimab-Libtayo melanoma study, which ultimately failed; notices cite an earlier decline of roughly $102 per share from the class-period high. The repeated announcements increase litigation visibility and could keep a risk discount on the shares. Hagens Berman class-action notice Robbins Geller deadline notice
• Negative Sentiment: Analyst commentary also highlighted reasons to avoid REGN, including recent underperformance versus the broader market, adding to the cautious tone around the shares. Reasons to avoid REGN

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.